Retrospective comparions between high- and reduced-dose regimens.
| Study . | Regimen . | Disease . | No. . | Age, y (range) . | Relapse, % . | OS, % . | PFS, % . | Cause of death other than relapse . |
|---|---|---|---|---|---|---|---|---|
| *Relapse of low-grade NHL was similar to the conventional-dose regimen but the rate in aggressive NHL was higher. | ||||||||
| Abbreviations: OS, overall survival; PFS, progression-free survival; RIC, reduced-intensity conditioning; TBI, total-body irradiation; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; Cy, cytarabine; TRM, treatment-related mortality; GVHD, graft-vs-host disease; NHL, non-Hodgkin lymphoma; Bu, busulfan | ||||||||
| Scott34 | ||||||||
| RIC | 2 Gy TBI + fludarabine | AML/MDS | 38 | 53 (40–65) | 40 | 28 | 27 | TRM 8% GVHD/Infection 36% Graft failure 16% |
| Conventional dose | Busulfan + Cy | 112 | 62 (40–70) | 38 | 48 | 44 | TRM 24% GVHD/Infection 33% Graft failure <2% | |
| Rodriguez35 | ||||||||
| RIC | Fludarabine + melphalan | NHL | 40 | 51 (20–67) | 28* | 53 | 40 | TRM 28% |
| Conventional dose | fTBI/Cy or Bu/Cy | 48 | 44 (18–54) | 13 | 52 | 46 | TRM 33% | |
| Study . | Regimen . | Disease . | No. . | Age, y (range) . | Relapse, % . | OS, % . | PFS, % . | Cause of death other than relapse . |
|---|---|---|---|---|---|---|---|---|
| *Relapse of low-grade NHL was similar to the conventional-dose regimen but the rate in aggressive NHL was higher. | ||||||||
| Abbreviations: OS, overall survival; PFS, progression-free survival; RIC, reduced-intensity conditioning; TBI, total-body irradiation; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; Cy, cytarabine; TRM, treatment-related mortality; GVHD, graft-vs-host disease; NHL, non-Hodgkin lymphoma; Bu, busulfan | ||||||||
| Scott34 | ||||||||
| RIC | 2 Gy TBI + fludarabine | AML/MDS | 38 | 53 (40–65) | 40 | 28 | 27 | TRM 8% GVHD/Infection 36% Graft failure 16% |
| Conventional dose | Busulfan + Cy | 112 | 62 (40–70) | 38 | 48 | 44 | TRM 24% GVHD/Infection 33% Graft failure <2% | |
| Rodriguez35 | ||||||||
| RIC | Fludarabine + melphalan | NHL | 40 | 51 (20–67) | 28* | 53 | 40 | TRM 28% |
| Conventional dose | fTBI/Cy or Bu/Cy | 48 | 44 (18–54) | 13 | 52 | 46 | TRM 33% | |